1 week Ago By ABMN Staff
Shares of Pharming Group ( NASDAQ:PHAR – Get Free Report ) traded up 10.3% on Monday . The stock traded as high as $8.
41 and last traded at $8.49. 5,462 shares were traded during mid-day trading, a decline of 14% from the average session volume of 6,343 shares.
The stock had previously closed at $7.69. Analysts Set New Price Targets Several equities research analysts have recently issued reports on PHAR shares.
Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock.
Oppenheimer lifted their price target on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th.
Finally, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th. Read Our Latest Analysis on PHAR Pharming Group Stock Performance Pharming Group ( NASDAQ:PHAR – Get Free Report ) last released its earnings results on Thursday, March 13th.
The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.
02). The company had revenue of $92.70 million for the quarter, compared to the consensus estimate of $76.
67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.
65%. As a group, sell-side analysts forecast that Pharming Group will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group ( NASDAQ:PHAR – Free Report ) by 16.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Institutional investors and hedge funds own 0.03% of the company’s stock. Pharming Group Company Profile ( Get Free Report ) Pharming Group N.
V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter ..
